Clinical Research Directory
Browse clinical research sites, groups, and studies.
I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
Sponsor: Hasanuddin University
Summary
This study evaluates the potential of I-FALMIN, a supplement derived from toman fish (Channa micropeltes), as an additional source of albumin in patients with pulmonary tuberculosis. Tuberculosis patients often experience low albumin levels, which may slow down recovery. The purpose of this study is to determine whether giving I-FALMIN as a supplement, in addition to standard tuberculosis treatment, can improve albumin levels and support overall health status. The study will compare outcomes between patients who receive I-FALMIN and those who do not.
Official title: The Potential Development of I-FALMIN as a Phytopharmaca Candidate for Albumin Supplementation Derived From Toman Fish in Patients With Pulmonary Tuberculosis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2024-12-17
Completion Date
2025-10-20
Last Updated
2025-09-22
Healthy Volunteers
Yes
Conditions
Interventions
Investigational Drug
IFALMIN® is a standardized herbal preparation derived from Channa micropeltes (ikan toman), containing natural albumin. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
Placebo
Placebo capsule containing inert ingredients (such as starch/lactose), identical in appearance, size, and color to IFALMIN® capsule. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
Locations (1)
RSUD Wahidin Sudirohusodo
Makassar, South Sulawesi, Indonesia